Medifocus Inc. Announces Closing of Private Placement

(NOT FOR DISSEMINATION IN THE UNITED STATES OF AMERICA)

Medifocus Inc. (Medifocus or the Company) (TSX VENTURE:MFS)(OTCQX:MDFZF)
announces that it has completed its previously announced private placement. The
Company issued 22,196,795 units (each a Unit) at a price of $0.15 per Unit for
gross proceeds of $3,329,519.95. Each Unit is comprised of one common share (a
Common Share) and one Series C Common Share purchase warrant (a Warrant). Each
Warrant entitles the holder to purchase one additional Common Share at a price
of $0.20 for a period of 24 months following the completion of the Offering. If,
at any time prior to July 8, 2014, the daily volume weighted average trading
price of the Common Shares on the TSX Venture Exchange exceeds $0.75 for at
least 10 consecutive trading days, Medifocus may, within 30 days of such
occurrence, give an expiry acceleration notice to the holders of Warrants and,
if it does so, the Warrants will, unless exercised, expire on the 30th day after
the expiry acceleration notice is given. The Common Shares and Warrants issued
in connection with the private placement, and any Common Shares issued upon the
exercise of the Warrants, will have a hold period in Canada until January 22,
2012.


In connection with the private placement, subject to compliance with applicable
securities legislation and TSX Venture Exchange policies, a 7% finder's fee was
paid on $1,575,025 of the gross proceeds for an aggregate finder's fee of
$110,251.75.


The proceeds of this Offering will be primarily used to commercialize the newly
acquired Prolieve(R) line of business, for working capital and to continue
Medifocus' pivotal phase III clinical trials using Medifocus Microfocus APA 1000
System for the treatment of breast cancer (including all related professional
expenses).


Medifocus owns a patented microwave focusing technology platform (the Adaptive
Phased Array ("APA") technology), which can precisely target and control
microwave energy to cause heating in cancerous tumors anywhere in the body
reliably and repeatedly. The ability to target tumors with a precision
controlled dose of heat can be used to destroy tumors at higher temperatures, to
treat tumors in combination with chemotherapy and/or radiation at moderate
temperatures for increased effectiveness and reduced toxicity and to trigger the
targeted release of therapeutic drugs and genes at tumor sites at lower
temperatures. While the core technology has been licensed from the Massachusetts
Institute of Technology, Medifocus has further refined the precision of the
microwave focusing and control ability and developed a commercial system
dedicated exclusively for the treatment of Breast Cancer. With the acquisition
of Prolieve, Medifocus now owns in addition, a revenue generating commercial BPH
heat treatment product generating cash flow to support the development and
commercialization of other catheter based or APA based external focused heat
systems for targeted thermotherapy of deep seated tumors anywhere in the body.
Please visit www.medifocusinc.com for more details.

AlliancePharma Inc. (TSXV:APA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024